UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000001587
Receipt number R000001825
Scientific Title Therapeutic efficacy of olmesartan, telmisartan and amlodipine to compare with histologic improvement and addciation about AGTR1 gene polymorphisms in subjects with nonalcoholic steatohepatitis (NASH); randomized open-labeled prospective study.
Date of disclosure of the study information 2008/12/25
Last modified on 2008/12/18 12:23:45

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Therapeutic efficacy of olmesartan, telmisartan and amlodipine to compare with histologic improvement and addciation about AGTR1 gene polymorphisms in subjects with nonalcoholic steatohepatitis (NASH); randomized open-labeled prospective study.

Acronym

Therapeutic efficacy of olmesartan, telmisartan and amlodipine in subjects with nonalcoholic steatohepatitis (NASH)

Scientific Title

Therapeutic efficacy of olmesartan, telmisartan and amlodipine to compare with histologic improvement and addciation about AGTR1 gene polymorphisms in subjects with nonalcoholic steatohepatitis (NASH); randomized open-labeled prospective study.

Scientific Title:Acronym

Therapeutic efficacy of olmesartan, telmisartan and amlodipine in subjects with nonalcoholic steatohepatitis (NASH)

Region

Japan


Condition

Condition

Non-alcoholic steatohepatitis

Classification by specialty

Hepato-biliary-pancreatic medicine Endocrinology and Metabolism

Classification by malignancy

Others

Genomic information

YES


Objectives

Narrative objectives1

To investigate the efficacy of ARB and Ca-blocker to compare about liver lipid-metabolite alteration with histologic improvement in subjects with nonalcoholic steatohepatitis; check with AGTR1 gene polymorphism.

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Before and after 6 months of medication to nonalcoholic statohepatitis (NASH) patients, we assessed liver lipid-metabolite alteration for use minute lipid analyzer: LipoSEARCH, hepatic histologic features,and AGTR1 gene polymorphisms.

Key secondary outcomes

To measure the factors about NASH progressive marker as glucose and lipid metabolite, oxidative stress, visceral/subcutaneous fat area,liver TG content.


Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Individual

Blinding

Open -but assessor(s) are blinded

Control

Active

Stratification

YES

Dynamic allocation

NO

Institution consideration

Institution is not considered as adjustment factor.

Blocking

NO

Concealment

Pseudo-randomization


Intervention

No. of arms

3

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

administration of olmesartan (40mg daily) in 24 weeks.

Interventions/Control_2

administration of telmisartan (40mg daily) in 24 weeks.

Interventions/Control_3

administration of amlodipine (7.5mg daily) in 24 weeks.

Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

80 years-old >=

Gender

Male and Female

Key inclusion criteria

a.All patients complicate hypertension (sBP 140-179mmHg, dBP 90-109mmHg )

b.The biopsy-proven nonalcoholic steatosis(NASH) patient will be evaluated in this study.

c. All patients gave their written informed consent to participation in the study.

Key exclusion criteria

1)The patient with diabetes mellitus(HbA1c>6.2)
2) contraction of renal artery.
3) The criteria for exclusion from participation in the study: history of hepatic disease, such as chronic hepatitis C or concurrent active hepatitis B (serum positive for hepatitis B surface antigen), autoimmune hepatitis, primary biliary cirrhosis (PBC), sclerosing cholangitis, hemochromatosis, wilsons disease, and current or past consumption of more than 20g of alcohol daily.
4) an anamnesis of drug allergy to use.

Target sample size

60


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Koji Fujita

Organization

Yokohama-city university hospital

Division name

Division of Gastroenterology

Zip code


Address

3-9,fukuura,kanazawa-ku,yokohama,kanagawa,Japan

TEL

045-787-2640

Email



Public contact

Name of contact person

1st name
Middle name
Last name

Organization

Yokohama-city university hospital

Division name

Division of Gastroenterology

Zip code


Address


TEL

045-787-2800

Homepage URL


Email



Sponsor or person

Institute

Yokohama City University Hospital

Institute

Department

Personal name



Funding Source

Organization

none

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2008 Year 12 Month 25 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Date of protocol fixation

2008 Year 11 Month 19 Day

Date of IRB


Anticipated trial start date

2008 Year 12 Month 01 Day

Last follow-up date

2010 Year 03 Month 01 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2008 Year 12 Month 18 Day

Last modified on

2008 Year 12 Month 18 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000001825


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name